Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Close icon Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

Exagen Inc Registered Shs Stock , XGN

2.26 0.00 0.00%
Official Close 3/17/2023 NAS
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 03/17/2023 the closing price of the Exagen Inc Registered Shs share was $2.26 on NAS. Compared to the opening price on Friday 03/17/2023 on NAS of $2.34, this is a drop of 3.54%. Exagen Inc Registered Shs's market capitalization is $38.70 M by 16.32 M shares outstanding.
Is Exagen stock a Buy, Sell or Hold? Exagen stock has received a consensus rating of buy. The average rating score is and is based on 3 buy ratings, 0 hold ratings, and 0 sell ratings.
What was the 52-week low for Exagen stock? The low in the last 52 weeks of Exagen stock was 2.10. According to the current price, Exagen is 107.62% away from the 52-week low.
What was the 52-week high for Exagen stock? The high in the last 52 weeks of Exagen stock was 9.30. According to the current price, Exagen is 24.30% away from the 52-week high.
What are analysts forecasts for Exagen stock? The 3 analysts offering price forecasts for Exagen have a median target of 13.00, with a high estimate of 25.00 and a low estimate of 7.00. The median estimate represents a 17.38 difference from the last price of 2.26.

Exagen Stock Snapshot

2.25
Bid
100.00
Bid Size
2.37
Ask
200.00
Ask Size
3/17/2023
Date
8:00 PM
Time
4,733.00
Volume
2.36
Prev. Close
2.34
Open
38.70 M
Market Cap
16.32 M
Number of Shares
2.26
Day Low
2.36
Day High
2.26
2.10
52 Week Low
9.30
52 Week High
2.26
-6.57
P/E Ratio
58.46
Free Float in %
-2.19
EPS 2023
0.96
Book Value per Share
-1.88
Cash Flow per Share

Exagen Historical Prices

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Exagen Analyst Data

Total Analysts: 3
Buy Ratings: 3 Neutral Ratings: 0 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 7.00 Median: 13.00 Highest: 25.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Exagen Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
11/17/22 BTIG Research
Maintained Buy $7
11/15/22 Capital Depesche
Maintained Buy $7
04/15/21 Capital Depesche
Maintained Buy $25

Exagen Estimates* in USD

  2023 2024 2025 2026
Revenue 47 57 67 80
Dividend - - - -
Dividend Yield (in %) - - - -
EPS -2.19 -1.63 -1.36 -1.00
P/E Ratio -0.92 -1.23 -1.48 -2.01
EBIT -35 -25 -18 -10
EBITDA -34 -24 -18 -15
Net Profit -38 -29 -19 -11
Net Profit Adjusted -34 -25 - -
Pre-Tax Profit -37 -28 -23 -18
Net Profit (Adjusted) -23 - - -
EPS (Non-GAAP) ex. SOE - - - -
EPS (GAAP) -2.19 -1.63 -1.36 -1.00
Gross Income 23 32 40 53
Cash Flow from Investing -2 -3 -2 -2
Cash Flow from Operations -39 -25 -24 -15
Cash Flow from Financing 25 0 30 10
Cash Flow per Share -1.88 -1.32 - -
Free Cash Flow -26 -20 -10 2
Free Cash Flow per Share -1.80 -1.24 - -
Book Value per Share 0.96 -0.03 - -
Net Debt - - - -
Research & Development Exp. 9 10 11 15
Capital Expenditure 2 2 1 1
Selling, General & Admin. Exp. 50 49 47 56
Shareholder’s Equity 30 5 16 9
Total Assets 74 50 60 55
  Previous Quarter
ending 12/31/22 		Current Quarter
ending 03/31/23 		Next Quarter
ending 06/30/23 		Current Year
ending 12/31/23 		Next Year
ending 12/31/24
Earnings Estimates
No. of Analysts 5 4 4 5 4
Average Estimate -0.761 USD -0.658 USD -0.588 USD -2.188 USD -1.633 USD
Year Ago -0.420 USD -0.600 USD -0.780 USD - -2.188 USD
Publish Date 3/20/2023 5/10/2023 8/2/2023 - -
Revenue Estimates
No. of Analysts 5 4 4 5 4
Average Estimate 9 USD 9 USD 11 USD 47 USD 57 USD
Year Ago 13 USD 10 USD 9 USD - 47 USD
Publish Date 3/20/2023 5/10/2023 8/2/2023 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Exagen Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Hazeltine Mark 03/01/2023 3,667.00 190,205.00 n/a Sell No
Adawi Kamal 03/01/2023 3,667.00 188,271.00 2.30 Sell No
Hazeltine Mark 02/26/2023 100,000.00 193,872.00 n/a Buy No
Adawi Kamal 02/26/2023 100,000.00 191,938.00 n/a Buy No
Adawi Kamal 02/07/2023 5,821.00 91,938.00 2.69 Sell No
Hazeltine Mark 02/07/2023 5,821.00 93,872.00 2.69 Sell No
ABALLI JOHN 12/07/2022 90,000.00 440,000.00 2.68 Buy No
ABALLI JOHN 10/15/2022 350,000.00 350,000.00 n/a Buy No
Hazeltine Mark 02/28/2022 3,241.00 99,693.00 7.12 Sell No
Zack Debra 02/28/2022 3,241.00 84,259.00 7.12 Sell No
Adawi Kamal 02/28/2022 3,241.00 97,759.00 7.12 Sell No
Rocca Fortunato R. 02/28/2022 4,322.00 120,678.00 7.12 Sell No
Hazeltine Mark 02/03/2022 63,500.00 102,934.00 n/a Buy No
Zack Debra 02/03/2022 50,000.00 87,500.00 n/a Buy No
Adawi Kamal 02/03/2022 63,500.00 101,000.00 n/a Buy No
Rocca Fortunato R. 02/03/2022 75,000.00 125,000.00 n/a Buy No
Johnson Wendy S. 09/02/2021 1,000.00 1,000.00 14.02 Buy No
TULLIS JAMES L L 08/04/2021 6,800.00 1,515,672.00 10.72 Sell No
TULLIS JAMES L L 08/03/2021 2,100.00 1,522,472.00 11.39 Sell No
TULLIS JAMES L L 08/02/2021 4,300.00 1,524,572.00 11.77 Sell No
TULLIS JAMES L L 08/01/2021 1,800.00 1,528,872.00 11.92 Sell No
TULLIS JAMES L L 06/28/2021 5,379.00 1,530,672.00 14.67 Sell No
TULLIS JAMES L L 06/27/2021 10,858.00 1,536,051.00 14.98 Sell No
TULLIS JAMES L L 06/24/2021 8,763.00 1,546,909.00 16.03 Sell No
Hazeltine Mark 05/16/2021 1,934.00 39,434.00 0.26 Buy No

Exagen Dividend Calendar

Date Name Dividend *yield Currency
2021 Exagen Inc Registered Shs - - USD
2020 Exagen Inc Registered Shs - - USD
2019 Exagen Inc Registered Shs - - USD
2018 Exagen Inc Registered Shs - - USD
2017 Exagen Inc Registered Shs - - USD
2015 Exagen Inc Registered Shs - - USD
2014 Exagen Inc Registered Shs - - USD
2013 Exagen Inc Registered Shs - - USD
2012 Exagen Inc Registered Shs - - USD
*Yield of the Respective Date

Exagen Inc Registered Shs Calendar

Event Estimate Info Date
Press Conference - 03/20/2023
Earnings Report -0.761 USD Q4 2022 Earnings Release 03/20/2023
Earnings Report -0.658 USD Q1 2023 Earnings Release 05/10/2023
Earnings Report -0.588 USD Q2 2023 Earnings Release 08/02/2023
Earnings Report - Q3 2023 Earnings Release 11/14/2023
Earnings Report - Q4 2023 Earnings Release 03/19/2024

Exagen Inc Registered Shs Past Events

Event Actual EPS Info Date
Press Conference - - 11/14/2022

Exagen Profile

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
9
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Exagen Shareholder

Owner in %
Freefloat 58.46
Hightower Trust Co. NA 16.44
Sun Mountain Capital LLC 14.15
H.I.G. Capital LLC (Private Equity) 10.39
Tullis Health Investors, Inc. 9.42
Cowen & Co. LLC 8.48
RTW Investments LP 8.36
Hunt Cos., Inc. 6.20
Wasatch Advisors, Inc. 6.13
Cowen & Co. LLC 5.92
Wasatch Ultra Growth Fund 5.87
Laurence W. Lytton 5.34
Stonepine Capital Management LLC 5.23
RTW Investments LP 5.03
Wasatch Micro Cap Fund 3.53
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.